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The long-lasting anticoagulant effect of vitamin K antagonists can be problematic in
cases of adverse drug reactions or when patients are switched to another anticoagulant
therapy. The objective of this study was to examine in silico the anticoagulant effect
of rivaroxaban, an oral, direct Factor Xa inhibitor, combined with the residual effect of
discontinued warfarin. Our simulations were based on the recommended anticoagulant
dosing regimen for stroke prevention in patients with atrial fibrillation. The effects of the
combination of discontinued warfarin plus rivaroxaban were simulated using an extended
version of a previously validated blood coagulation computer model. A strong synergistic
effect of the two distinct mechanisms of action was observed in the first 2–3 days
after warfarin discontinuation; thereafter, the effect was close to additive. Nomograms
for the introduction of rivaroxaban therapy after warfarin discontinuation were derived for
Caucasian and Japanese patients using safety and efficacy criteria described previously,
together with the coagulation model. The findings of our study provide a mechanistic
pharmacologic rationale for dosing schedules during the therapy switch from warfarin to
rivaroxaban and support the switching strategies as outlined in the Summary of Product
Characteristics and Prescribing Information for rivaroxaban.
Keywords: coagulation, combination therapy, mathematical modeling, pharmacodynamics, rivaroxaban,
simulation, warfarin
INTRODUCTION
Many patients who require long-term vitamin K antagonist
(VKA; e.g., warfarin) therapy experience difficulties in maintain-
ing a therapeutic international normalized ratio (INR) (Ageno
et al., 2012). Some patients may benefit from switching to one
of the direct oral anticoagulants, such as rivaroxaban, which have
been approved for the management of several thromboembolic
disorders, including the prevention of stroke and systemic
embolism in adult patients with non-valvular atrial fibrillation
and at least one other risk factor for stroke. Rivaroxaban has
been approved in this indication in Europe and the United States
(at a dose of 20mg once daily) (Bayer Pharma, 2014; Janssen
Pharmaceuticals Inc., 2014) and in Japan (at a dose of 15mg once
daily) (Bayer Yakuhin Ltd., 2012; Hori et al., 2012).
VKAs are indirect anticoagulants that target multiple enzymes
in the coagulation cascade. Specifically, they inhibit vitamin
K-dependent clotting factors including Factors II, VII, IX, and
X, and they also inhibit the carboxylation of the anticoagulant
proteins C and S; therefore, VKAs have the potential to be pro-
coagulants (Ansell et al., 2008). The use of VKAs is associated
with the need for frequent monitoring and dose adjustment
(Ansell et al., 2008) to ensure that the INR reaches and remains
within the recommended therapeutic range (Ansell et al., 2008;
Douketis et al., 2008; Kearon et al., 2012). The INR, based on the
prothrombin time (PT) coagulation test, was developed to pro-
vide a standardized measure of the anticoagulant effect of VKAs
and is the basis of guidelines for warfarin therapy (Ageno et al.,
2012). Target INR values established for VKA therapies are spe-
cific to the distinct mechanisms of action of these agents and
cannot be translated to anticoagulants with different mechanisms
of action. For example, INR values measured in the therapeutic
range of rivaroxaban are significantly lower than those required
under warfarin therapy, indicating that INR measurements are
not valid in this case (Kubitza et al., 2005a,b; Ansell et al., 2008;
Douketis et al., 2008; Kearon et al., 2012).
Dose–response relationships of VKAs may be influenced by
genetic factors, drug–drug interactions, and the consumption of
alcohol and foods containing vitamin K (Ansell et al., 2008).
For example, mutations in the vitamin K oxide reductase gene
lead to enzymes with varying sensitivities to warfarin inhibition.
Different ethnic populations vary in the frequency with which
these mutations occur and, therefore, require different warfarin
doses to maintain a therapeutic INR.
After discontinuation of warfarin, the concentrations of active
vitamin K-dependent clotting factors and anticoagulant proteins
C and S increase slowly toward normal levels. Because all of these
factors are generated and cleared slowly, coagulation behavior
is normalized only several days after warfarin discontinuation.
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Therefore, transitioning between warfarin and rivaroxaban ther-
apies must be managed carefully and must account for the slow
onset and long washout of warfarin effects to minimize the risk of
bleeding and thrombotic events (Faaij et al., 2001, 2002; Reiffel,
2004; Patel et al., 2011).
Rivaroxaban is an oral, direct Factor Xa inhibitor with a wide
therapeutic window (Perzborn et al., 2005; Roehrig et al., 2005)
and predictable pharmacokinetic (PK) and pharmacodynamic
(PD) properties. Because of its mechanism of action, rivarox-
aban influences routine coagulation assays such as the PT/INR
and activated partial thromboplastin time (aPTT). Phase I stud-
ies have shown a close correlation between PT and rivaroxaban
plasma levels (Kubitza et al., 2005a,b).
In a previous study, we used an ordinary differential equation
(ODE)-based computer model for blood coagulation to assess the
optimal balance between efficacy and safety scenarios for rivarox-
aban (Burghaus et al., 2011). This model was based on prior
knowledge about coagulation factor concentrations after anti-
coagulant administration and data from ex vivo clotting tests; the
model structurally resembles other recently published models of
the effect of rivaroxaban on coagulation (Orfeo et al., 2010, 2011).
When modeling coagulation behavior during the transition
phase from warfarin to rivaroxaban, the long PK and PD decay
of warfarin, in conjunction with the effect of both warfarin and
rivaroxaban on coagulation characteristics such as PT, need to
be considered.
Currently, there is a lack of clinical data regarding PD changes
during the transition from VKA therapy to direct oral anticoagu-
lants, including rivaroxaban. Therefore, data derived from mod-
eling approaches will provide useful information for clinicians
planning to investigate the switch of medication experimentally.
The computational model used in this study was composed
of the coagulation model as published by Burghaus et al. (2011),
and the warfarin decay model describing the time course of coag-
ulation factor concentrations as a result of warfarin treatment or
its discontinuation. This model was used to investigate changes
in the combined coagulation effect during the switch from war-
farin to rivaroxaban. Our objectives were to improve mechanistic
understanding of the interaction between warfarin and rivaroxa-
ban during the transition and to provide a mechanistic pharma-
cologic rationale for dosing schedules during the therapy switch,
thereby supporting the switching strategies as outlined in the
Summary of Product Characteristics and Prescribing Information




We simulated the effect of warfarin monotherapy and the com-
bined effects of warfarin and rivaroxaban using an ODE-based
blood coagulation model that represents coagulation in ex vivo
clotting tests with human plasma such as PT and aPTT; the
model has been described previously (Burghaus et al., 2011) and
is based largely on several published models (Kogan et al., 2001;
Hockin et al., 2002; Anand et al., 2003; Bungay et al., 2003;
Orfeo and Mann, 2005). The model, as described previously
by Burghaus et al. (2011), takes into account both the intrinsic
and extrinsic pathways of the coagulation cascade, as well as
the common pathways leading to fibrin generation via throm-
bin (Figure 1). As such, it possesses some unique features that
were not included in earlier models, such as a portfolio of drug
action mechanisms. Study drugs were modeled by closely rep-
resenting their anticoagulant properties (Burghaus et al., 2011).
Supplementary Material 1—Model Pack, provides the complete
model as implemented inMoBi® and all (Matlab®) codes used for
simulations and generation of figures. This provides full insight
into the processes of computational warfarin titration and the
parameters used for the simulations.
By use of parameter studies, the model can be used to investi-
gate scenarios of blood coagulation initiated by very weak triggers
that cannot be investigated in a controlled manner in experimen-
tal assays. For the simulations in this study we used the previously
described model and added a turnover model for the synthesis
and decay of vitamin K-dependent Factors II, VII, IX, and X, and
proteins C and S. Steady-state concentrations of these factors were
set as previously reported in Burghaus et al. (2011). In the current
study, model parameters that correspond to blood flow were set
to zero.
The mechanism of action of rivaroxaban was already imple-
mented in the previously described model (Burghaus et al.,
2011). However, warfarin action had to be newly implemented:
warfarin PK was not explicitly modeled. Both the steady-state
effect of warfarin and its decay after discontinuation of ther-
apy are represented by effective inhibition of synthesis rates of
vitamin K-dependent coagulation factors in a standard turnover
model. Parameters of the turnover model were chosen such
that steady-state conditions (starting concentrations) for vita-
min K-dependent factors of the turnover model corresponded
to previously published data (Wittkowsky, 2003). No PK interac-
tions between warfarin and rivaroxaban have been identified and,
therefore, such potential interactions were not accounted for in
the model (Food and Drug Administration, 2011; Johnson and
Johnson Pharmaceutical Research and Development, 2011).
Turnover model for vitamin K-dependent coagulation factors
The turnover model for vitamin K-dependent coagulation factors
(Table 1) describes the formation and clearance of the relevant
proteins. Coagulation factor clearance is implemented as an expo-
nential decay to reflect physiological conditions. The half-lives
used in the model were as follows (Table 1C): Factor II, 57 h;
Factor VII, 5 h; Factor IX, 25.5 h; Factor X, 37.5 h; protein C, 9 h;
protein S, 60 h (Wittkowsky, 2003).
Therapeutic warfarin is considered to be applied in a racemic
1:1 mixture of R-warfarin and S-warfarin. The effect of both war-
farin components was implemented as a pre-factor W reducing
the formation rates of coagulation factors according to the follow-
ing equation, with R-warfarin and S-warfarin representing the
respective effective concentrations (in arbitrary units; see below
and Supplementary Material 1):
W = ([R-warfarin + 3.25 × S-warfarin]2 + 1)−1
This equation takes into account that S-warfarin is, on average,
3.25-fold more potent than R-warfarin, with the square having
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FIGURE 1 | Overview of the processes accounted for by the coagulation
model. The blood coagulation model represents the biochemical reactions
that result in factor activation. The extrinsic and intrinsic pathways of the
model lead to thrombin and fibrin formation downstream of Factor Xa, known
as the common pathway. Drug action is represented by the competitive
inhibition of Factor Xa by rivaroxaban and by down-regulation of the vitamin
K-dependent synthesis (arched arrow) of the factors VII, IX, and X, and
prothrombin (Factor II) by warfarin. These structural elements of the
coagulation cascade, as well as proteins C and S (not depicted), formed the
basis of the model by Burghaus et al. (2011).
its rationale in the two steps inhibited by warfarin in the hydro-
quinone/epoxide cycle of the vitamin K process (Wittkowsky,
2003). S-warfarin and R-warfarin decay with half-lives of 29
and 45 h, respectively (Wittkowsky, 2003). Discontinuation of
warfarin is modeled by simulating the decay of R-warfarin and
S-warfarin, resulting in an increase in vitamin K-dependent fac-
tor production rates and thus factor concentrations. Figure 2
shows the obtained warfarin decay and factor increase plots over
a 10-day period (240 h).
The parameters R-warfarin and S-warfarin of the warfarin
decay model (Table 1), which are considered to be expressed
in arbitrary units of unknown proportionality to in vivo con-
centrations, were adjusted to reach the INR (corresponding to
steady-state warfarin treatment) that was chosen as a starting
point for the respective warfarin discontinuation simulation. For
example, the warfarin parameter resulting in an INR of 2.5 and
relative factor concentrations of approximately 30% was found
to be 0.4 (Figure 2), in line with actual clinical observations
(Ferreira et al., 2002).
The warfarin action and decay model was programmed in
MoBi® 2.3 (Bayer Technology Services, Leverkusen, Germany)
(Bayer Technology Services, 2010), as were the already pub-
lished model components (see listing of model parameters in
Table 1).
SIMULATIONS
Simulation of coagulation status during switching
In general, to simulate the coagulation status during a switch
from warfarin to rivaroxaban, we focused on drug–drug combi-
nation effects as characterized by the PT test and trigger scenarios
considered relevant for bleeding risks as well as antithrombotic
efficacy (Table 2). The latter scenarios have been established and
tested previously (Burghaus et al., 2011). In clinical practice PT
values are commonly reported as INR values to indicate the anti-
coagulant effect of VKAs. Therefore, for comparison with clinical
data, simulated PT test results were translated into INR values
assuming an ISI (International Sensitivity Index; a characteristic
of in vitro PT reagents used for calibration of experimental data)
value for our in silico PT assay of 1.0.
Starting conditions for simulations of switching were set by
adjusting the effective concentration of R- and S-warfarin (and
the resulting steady-state concentrations of vitamin K-dependent
factors) to represent steady-state warfarin therapies at a chosen
INR value, including INRs below (1.5), within (2.5), and above
(3.5) the therapeutic window. For a given time point after discon-
tinuation of warfarin therapy, the effective concentrations of R-
and S-warfarin were calculated using the decay model.
To evaluate the model, we first simulated the decay of war-
farin without addition of rivaroxaban and compared it with data
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Table 1 | The warfarin decay model: (A) reaction; (B) species; (C) species half-lives.
(A) REACTIONS IN THE WARFARIN DECAY MODEL
Reaction name Stoichiometry Kinetics
RfII–decay fII → inactive species* fII × ln(2)/t½ fII
RfII–formation Profactor* → fII (kfII × ln(2)/t½ fII)/(formation rate + 1)
RfIX–decay fIX → inactive species* fIX × ln(2)/t½ fIX
RfIX–formation Profactor* → fIX (kfIX × ln(2)/t½ fIX)/(formation rate + 1)
RfVII–decay fVII → inactive species* fVII × ln(2)/t½ fVII
RfVII–formation Profactor* → fVII (kfVII × ln(2)/t½ fVII)/(formation rate + 1)
R-warfarin–decay R-warfarin → inactive species* R-warfarin × ln(2)/t½ R-warfarin
S-warfarin–decay S-warfarin → inactive species* S-warfarin × ln(2)/t½ S-warfarin
RfX–decay fX → inactive species* fX × ln(2)/t½ fX
RfX–formation Profactor* → fX (kfX × ln(2)/t½ fX)/(formation rate + 1)
Protein C–decay Protein C → inactive species* Protein C × ln(2)/t½ Protein C
Protein C–formation Profactor* → Protein C (kProtein C × ln(2)/t½ Protein C)/(formation rate + 1)
Protein S–decay Protein S → inactive species* Protein S × ln(2)/t½ Protein S
Protein S–formation Profactor* → Protein S (kProtein S × ln(2)/t½ Protein S)/(formation rate + 1)
(B) KEY PARTICIPANTS IN THE WARFARIN DECAY MODEL
Species Initial concentration (M)
fII 1.40 × 10−6
fIX 9.00 × 10−8
fVII 1.00 × 10−8
Effective R-warfarin/ S-warfarin* Fitted to obtain start INR
fX 1.60 × 10−7
Protein C 6.00 × 10−8
Protein S 1.40 × 10−7
Protein C/S binding sites on phospholipids 3.60 × 10−6
(C) TYPICAL HALF-LIFE (t½) FOR SPECIES IN THE WARFARIN DECAY MODEL
Species (half-life) Time (s)
t½ fII 205,200 (57 h)
t½ fIX 91,800 (25.5 h)
t½ fVII 18,000 (5 h)
t½ fX 135,000 (37.5 h)
t½ protein C 32,400 (9 h)




Note for Table A: For the calculation of the formation rate, see section on Turnover model for vitamin K-dependent coagulation factors in the Materials and Methods.
*Indicates a ‘boundary species’ that has its value kept constant during the simulation. f, Factor; k, kinetic rate constant; R, reaction; t½, half-life.
Note for Table B:*Effective R-warfarin and S-warfarin concentrations are in arbitrary units reflecting the fraction of remaining warfarin.
Factor concentrations (II, VII, IX, X) are average plasma concentrations taken from Hockin et al. (2002). Protein C and S concentrations were taken from Bungay et al.
(2003); protein S was corrected to reflect the free plasma concentration (40% of total) reported in the protein C monograph available online at www .chromogenix.
com. f, Factor; INR, international normalized ratio.
Note for Table C: †74,897 for Japanese patients. f, Factor.
from a clinical study of warfarin discontinuation. We then inves-
tigated the interaction with rivaroxaban as characterized by a PT
test (and the resulting INR values) by re-running the warfarin
decay simulations with added rivaroxaban, testing a broad range
of rivaroxaban concentrations.
Simulations of the therapeutic corridor in Caucasian patients
To evaluate the safety and efficacy of rivaroxaban combined
with residual warfarin action in virtual Caucasian patients, we
used simulation to identify threshold rivaroxaban concentrations
leading to the same clotting times in previously established
trigger scenarios (Burghaus et al., 2011), as obtained for war-
farin monotherapy at INR values of 1.5, 2.0, 4.0, and 5.0.
These INR values are within the INR range considered to
be of clinical relevance (Ageno et al., 2012) for the follow-
ing reasons: the target therapeutic range of INRs for anti-
coagulation is generally between 2.0 and 3.0; special patient
populations may need to be adjusted to lower INR ranges; and
an INR higher than 3.0 is not uncommon in patients receiving
VKA therapy.
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FIGURE 2 | Dynamic behavior of the warfarin decay model. Graphs on the
left side show the sudden onset of warfarin therapy simulated for
Caucasians. Graphs on the right side show warfarin discontinuation,
eventually leading to normal values for the coagulation system. Upper graphs
show the values of R-warfarin and S-warfarin (arbitrary units); middle graphs
show the corresponding evolution of factor concentrations; and lower graphs
show coagulation time (relative to an untreated scenario) for different triggers
(Table 2) in the coagulation model, depending on the factor concentrations
from the middle graphs. PK, pharmacokinetics; PT, prothrombin time; TF,
tissue factor; t½, half-life.
Table 2 | Coagulation scenarios used for simulations.
Scenario Tissue factor concentration (M)
Prothrombin time test (extrinsic) 4.0 × 10−9
Extrinsic strong 10−11
Extrinsic weak 10−14
The strong extrinsic trigger (TF = 10−11 M) was assumed to
be the relevant safety scenario. The weak extrinsic trigger (TF
= 10−14 M) was considered to be the relevant efficacy scenario. A
safe rivaroxaban exposure was assumed to provide faster clotting
after the strong trigger than warfarin therapies with INR values of
4.0 and 5.0 for patients with a high and a normal risk of bleeding,
respectively. An efficacious rivaroxaban scenario was assumed to
extend clotting times after the weak trigger beyond those times
obtained for warfarin therapies at INR values of 1.5 and 2.0
for patients with normal and high thrombotic risk, respectively.
These safety and efficacy thresholds were calculated for each time
point during the first 7 days after warfarin discontinuation. The
impact of INR at the time of discontinuation was evaluated by
simulating initial INR values of 1.5, 2.5, and 3.5. The impact of
warfarin PK variability was studied by simulating different half-
lives. We used typical slow, median, and fast half-lives for S- and
R-warfarin (52, 29, and 18 h for S-warfarin, and 70, 45, and 20 h
for R-warfarin, respectively).
Simulations of the therapeutic corridor in Japanese patients
We also performed simulations in virtual Japanese patients. In the
Japanese population, the variability of clearance via cytochrome
P450 2C9 is lower than in most other populations (Takahashi
et al., 2006). When simulating warfarin discontinuation for the
Japanese population, we adjusted the half-life of S-warfarin by
multiplying the typical values used for Caucasians with a relative
clearance (469.4/654.3) for Japanese versus Caucasian patients
as determined previously (Takahashi et al., 2006). The only
well-documented difference in the coagulation cascade in the
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Japanese population is a reduced level of Factor VII pre-activation
of 0.5% as compared with 1.0% in Caucasians (Kario et al., 1994);
this difference was accounted for in the Japanese model. In the
simulations of Japanese patients, R-warfarin and coagulation fac-
tor half-lives, as well as their variability ranges, were the same as
for the Caucasian simulations.
Impact of differences in coagulation factor expression status
To assess the robustness of our study approach for differences
in coagulation factor expression status (e.g., as a consequence
of genetic predisposition), we repeated the above simulation
program for a broad panel of in silico patients with different
factor abnormalities (over- or under-expression in Factors I,
V, VIII, and XI; Table 3 and Supplementary Material 2). These
factors were chosen because they are independent of warfarin.
Consequently, their levels do not vary depending on the dose
of warfarin and they can be used to evaluate the sensitivity of
the model.
RESULTS
To obtain initial conditions for the simulation of the discontinua-
tion of warfarin therapy the effect of adding warfarin and its effect
on factor synthesis was simulated until steady-state conditions
were reached. Figure 2 illustrates the effect of setting the effective
Table 3 | Simulation program for patients with factor abnormalities.
Factor I Factor V Factor VIII Factor XI
Normal patient 1 1 1 1
Factor I deficient 0.15 1 1 1
0.5 1 1 1
0.75 1 1 1
2 1 1 1
5 1 1 1
Factor V deficient 1 0.01 1 1
1 0.1 1 1
1 0.5 1 1
1 0.75 1 1
1 2 1 1
1 5 1 1
Factor VIII deficient 1 1 0.01 1
1 1 0.1 1
1 1 0.5 1
1 1 0.75 1
1 1 2 1
1 1 5 1
Factor XI deficient 1 1 1 0.01
1 1 1 0.1
1 1 1 0.5
1 1 1 0.75
1 1 1 2
1 1 1 5
The values presented are ratios of normal values.
warfarin concentration to 0.4 (upper left panel) on the tempo-
ral change of relative factor concentrations (middle left panel;
for all three trigger scenarios) and the resulting increase in clot-
ting times (lower left panel) over 10 days. The simulation of the
discontinuation of warfarin treatment (Figure 2) showed a slow
exponential decay of the effective S- and R-warfarin concentra-
tions (Figure 2, upper right panel). Concentrations of vitamin
K-dependent factors returned slowly to baseline values, defined
as values in the absence of warfarin treatment (1.0; Figure 2, mid-
dle right panel), although some factors took more than 10 days to
reach 100% of baseline values. Similar timescales were obtained
for the decay of clotting time prolongation (Figure 2, lower right
panel). Simulation data of coagulation factors were a good fit to
clinical data from a warfarin discontinuation study (White et al.,
1995), as shown in Figure 3.
Next, we investigated the impact of different warfarin half-
lives on the decay of INR (Figure 4). We simulated typical slow,
median, and fast half-lives for S- and R warfarin (52, 29, and 18 h
for S-warfarin, and 70, 45, and 20 h for R-warfarin, respectively)
(see Methods section) and plotted time-dependent changes in
INR over 7 days (Figure 4; black lines and gray shaded area). We
simulated the effect of rivaroxaban on PT and INR by adding
constant concentrations of rivaroxaban to the simulated decay of
warfarin action. At the time of discontinuation, a concentration
of 200µg/L rivaroxaban increased PT values from approximately
30 s owing to the warfarin effect from an INR of 2.5 to more
than 50 s (Figure 4; red lines and shaded area), indicating a syn-
ergistic effect. Rivaroxaban alone at a concentration of 200µg/L
without any warfarin effect prolonged PT by 3 s from 12 s to
approximately 15 s (Figure 4; light blue horizontal lines). A puta-
tive, only additive interaction between warfarin and rivaroxaban
FIGURE 3 | Validation of the warfarin decay model. Thin colored lines
represent the international normalized ratio (INR) data of 13 individual
patients after discontinuation of warfarin therapy (White et al., 1995)
(individual data courtesy of R.H. White, UC Davis, California, USA); the thick
black line provides the associated median at every time point; the thick red
line describes the simulated INR during warfarin decay.
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FIGURE 4 | Synergistic effect of warfarin and rivaroxaban (200µg/L)
after warfarin discontinuation. Black lines show the prothrombin time
(PT) as a function of time after warfarin discontinuation, starting at an
international normalized ratio (INR) of 2.5, simulated for Caucasians.
Rivaroxaban exposure of 200µg/L causes a PT prolongation of about 3 s in
a patient not on warfarin therapy. Blue lines show the hypothetical additive
effect of warfarin and rivaroxaban exposure of 200µg/L. Red lines show the
actual simulation of the effect of decaying warfarin plus rivaroxaban
(synergistic effect). The center lines are simulated for typical warfarin
half-life; lower and upper lines show the same experiments for fast and
slow warfarin decay, respectively, using half-lives as reported previously
(Wittkowsky, 2003). Light blue lines show the effect of different degrees of
rivaroxaban exposure for comparison.
would, therefore, only explain an increase of PT from 30 to 33 s
(Figure 4; blue lines and shaded area).
The slope of the PT versus rivaroxaban concentration relation-
ship is a measure of rivaroxaban potency. A systematic analysis
of the time dependency of this slope after warfarin discontinua-
tion showed that the strongest synergism occurred directly after
discontinuation (Figure 5A). For up to 72 h after discontinua-
tion, the slope was clearly steeper than for rivaroxaban alone
(t = inf; Figure 5A). A similar pattern was demonstrated for
simulations with Japanese in silico patients (see Materials and
Methods; Figure 5B), which also showed the faster warfarin decay
in these patients as a consequence of the shorter S-warfarin
half-life compared with Caucasian patients (see Materials and
Methods). Differences between the Japanese and Caucasian pop-
ulations were observed both at the level of the relative concen-
trations of individual coagulation factors (Figure 5C) as well as
in the resulting relative PT values (Figure 5D). These analyses
showed the biggest difference between Caucasian and Japanese
patients at around 2 days after warfarin discontinuation.
Next, we simulated a typical warfarin decay scenario over a
7-day period (168 h) for an initial INR of 2.5 at discontinuation
for Caucasian patients and calculated efficacy and safety corridors
for rivaroxaban exposure. These corridors were defined by clot-
ting time thresholds for extrinsic triggers (Table 2) as obtained
for treatment with warfarin only corresponding to INR val-
ues of 1.5, 2.0, 4.0, and 5.0. The results were translated into a
nomogram (Figure 6) depicting the rivaroxaban concentration
FIGURE 5 | Prothrombin time (PT) characteristics for rivaroxaban after
warfarin discontinuation. (A,B) Solid black line represents the effect of
rivaroxaban without warfarin. The impact of rivaroxaban is stronger when
rivaroxaban therapy is started early after warfarin discontinuation. (A)
Modeled for the Caucasian population. (B) Modeled for the Japanese
population. (C,D) Time course of (C) vitamin K-dependent factor
(Continued)
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FIGURE 5 | Continued
concentration ratios and (D) PT ratio of simulated Japanese versus
Caucasian patients. Vitamin K-dependent factors start from 40% of the
normal for both Japanese and Caucasians. (D) The tissue factor (TF) value
used to simulate PT was set at 4 × 10−9 M. The simulated Japanese
normal PT is slightly higher than the simulated Caucasian normal PT
because of reduced Factor VII preactivation, resulting in a ratio >1 after the
warfarin effect has subsided (8–10 days). Inf, infinite time (after warfarin
discontinuation); INR, international normalized ratio.
FIGURE 6 | Nomogram for a typical warfarin decay scenario starting at
an international normalized ratio (INR) of 2.5 for the Caucasian in silico
patient. The x-axis describes the time after discontinuation of warfarin and
the y-axis corresponds to rivaroxaban exposure. Blue and red lines
correspond to the edges of the safety and efficacy regions. The strong
extrinsic trigger (TF = 10−11 M) was assumed to be the relevant safety
scenario. The weak extrinsic trigger (TF = 10−14 M) was considered to be
the relevant efficacy scenario. Rivaroxaban exposure above the dashed red
line is considered to be safe and exposure below the dashed blue line is
considered to be efficacious for most patients. The region between the
solid red and solid blue lines describes the exposure range to which
patients with a high risk of bleeding or thrombosis should be dosed.
Patients with a high risk of bleeding should stay below the exposure limit
represented by the solid red line. Patients with a high risk of thrombosis
should stay above the exposure limit represented by the solid blue line.
Alternative y-axes convert rivaroxaban exposure into mean plasma
concentration (Cmean), maximum plasma concentration (Cmax), and
minimum plasma concentration (Ctrough) values for the different rivaroxaban
dosing regimens studied (5, 10, 15, and 20mg once daily [OD]).
Pharmacokinetic curves for rivaroxaban 10 and 20mg OD are drawn in
black. These nomograms do not account for pharmacokinetic variability or
uncertainty in parameters. However, the potential impact of
pharmacokinetic variability of rivaroxaban can also be evaluated from this
graph although this is not depicted explicitly.
range compliant with the calculated thresholds. The nomogram
illustrates that the therapeutic window for rivaroxaban is nar-
rower at the time of discontinuation of warfarin and widens in
the subsequent days before it reaches the full width as given
for monotherapy without warfarin co-medication. To relate the
exposure window to rivaroxaban PK, the y-axis was enriched with
information about trough, mean, and peak concentrations for 5,
FIGURE 7 | Nomogram for a typical warfarin decay scenario starting at
an international normalized ratio (INR) of 2.5 for the Japanese in silico
patient. Pharmacokinetic curves for rivaroxaban 10 and 15mg OD are
drawn in black. (Note: please refer to legend of Figure 6 for further details.)
10, 15, and 20mg once-daily doses of rivaroxaban. We plotted
the mean PK profile resulting from a rivaroxaban dosing schedule
starting with 10mg once daily on day 1 after discontinuation, and
continuing with rivaroxaban 20mg once daily (the dose approved
in Europe and the United States for the prevention of stroke and
systemic embolism in patients with atrial fibrillation) (Figure 6).
The superimposed PK profile shows that day-end levels were
within the safety limit. Therefore, the graph demonstrates that
this schedule is compliant with the in silico safety and efficacy
criteria (red and blue lines, respectively).
The same type of simulation was performed for the safety and
efficacy corridor for in silico Japanese patients starting at an INR
of 2.5 (Figure 7). The mean rivaroxaban concentrations for two
consecutive days with 10mg once daily starting on day 2 after war-
farin discontinuation followed by rivaroxaban 15mg once daily
doses comply with the calculated corridor. The information about
mean, peak, and trough concentrations of rivaroxaban are also
provided in the nomogram allowing assessment of safety and effi-
cacy of other dosing schedules. For instance, a schedule starting
on day 1 with 5mg once daily, continuing with a daily increase
to 10mg once daily and finally 15mg once daily on day 3, would
also match the corridor.
We also investigated the effect of different baseline INR lev-
els at discontinuation. With an INR of 1.5 at discontinuation,
we found that a flat rivaroxaban schedule of 20mg once daily
started already on day 0, when the next warfarin dose would be
due, matched the in silico criteria (Figure 8A). For comparison
we have plotted the same dosing schedule as for the simulation
starting at an INR of 2.5. By design, the lower efficacy threshold
was above 0 immediately after discontinuation leading to the need
to dose rivaroxaban in order to stay within the corridor. With an
INR of 3.5 at discontinuation, the safety and efficacy corridor was
very narrow just after discontinuation (Figure 8B). As for simu-
lations with an initial INR of 2.5, the superimposed PK profile
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FIGURE 8 | Comparison of nomograms for patients with INR of (A) 1.5
and (B) 3.5 (typical warfarin decay is assumed). Pharmacokinetic curves
for rivaroxaban 10 and 20mg OD are drawn in black. For panel (A), the
dashed blue line representing the upper exposure limit for normal patients
extends past the axis limits of the figure and is, therefore, not presented on
the graph. (Note: please refer to legend of Figure 6 for further details.)
shows that day-end levels were within the safety limit. The nomo-
gram suggests starting with rivaroxaban 10mg once daily only on
day 2 after warfarin discontinuation when the therapeutic win-
dow has already broadened, followed by rivaroxaban 20mg once
daily from day 3 onwards.
We then investigated the impact of the PK half-life of war-
farin. We repeated the simulations for Caucasian patients starting
at an INR of 2.5 but used half-life combinations with the slow-
est and fastest decay rather than the mean values used previously
(Figures 6–8; mean half-lives: S-warfarin 29 h, R-warfarin 20 h).
For fast decay, we used the following half-lives: S-warfarin 18 h
and R-warfarin 45 h (Figure 9A). For slow decay we used half-
lives for S-warfarin of 52 h and for R-warfarin of 70 h (Figure 9B).
As expected, a faster PK decay of warfarin broadened the safety
and efficacy corridor early (Figure 9A); the dosing schedule as
FIGURE 9 | Comparison of nomograms for patients with a starting INR
of 2.5, assuming (A) fast or (B) slow warfarin decay. Pharmacokinetic
curves for rivaroxaban 10 and 20mg OD are drawn in black. (Note: please
refer to legend of Figure 6 for further details.)
suggested for normal warfarin half-lives (Figure 6) complies with
the safety and efficacy corridor in this scenario. The slower decay
led to a slower broadening of the corridor this time, suggesting a
delayed start of rivaroxaban dosing on day 2 (Figure 9B).
Finally, we repeated the calculations for the Caucasian base
case starting at an INR of 2.5 with in silico patients charac-
terized by the over- or under-expression of various coagulation
factors (Table 3; Supplementary Material 2). Only non-vitamin
K-dependent factors (Factors I [fibrinogen], V, VIII, and XI)
were chosen for this analysis because these can be consid-
ered to be independent of warfarin. Variations in Factors VIII
or XI showed little impact on the overall appearance of the
safety and efficacy corridors even at extreme over- or under-
expression (Supplementary Material 2). At the lower end of the
Factor I and V concentrations, the corridors were shifted toward
lower levels, illustrating an overall increase in bleeding risk.
At the upper extreme of Factor V over-expression the lower
www.frontiersin.org November 2014 | Volume 5 | Article 417 | 9
Burghaus et al. Warfarin to rivaroxaban switching model
efficacy threshold was clearly increased. Factor I increases had
little impact.
DISCUSSION
We used a computational coagulation model to investigate
changes in the combined coagulation effect during the switch
from warfarin to rivaroxaban in Caucasian and Japanese in silico
patients. Our model was an extended version of a previously
evaluated ODE-based coagulation model (Burghaus et al., 2011).
We added a vitamin K-dependent factor turn-over model and
an effective warfarin action and decay module. The model was
structurally similar to published models by Wajima et al. (2009)
and Orfeo et al. (2010, 2011). Our model also represents war-
farin enantiomers and enantiomer-specific differences in warfarin
clearance between Caucasian and Japanese patients (Takahashi
et al., 2006). Warfarin PK is modeled via effective warfarin
concentrations with respect to the resulting inhibition of the
synthesis of vitamin K-dependent factors. Warfarin clearance is
implemented as a decay of the inhibition of synthesis.
Our model only implicitly takes into account that the
dose–response relationship of warfarin is dependent on genetic
and environmental factors such as food and concomitant drugs.
These factors may influence the PK (e.g., the decline of concen-
trations because of metabolic clearance of both S-warfarin and
R-warfarin enantiomers) and the PD of warfarin (e.g., by pro-
vision of higher concentrations of vitamin K, which counteracts
VKA action; Ansell et al., 2008).
To evaluate the warfarin action and decay module, we com-
pared the simulated decay of warfarin effect on INR with clinical
data from a warfarin discontinuation study (Figure 3) (White
et al., 1995) and obtained a high level of agreement. Because
the model parameters were not fitted to match the clinical dis-
continuation data used by White et al. (1995) but taken from
independent published experimental data (Wittkowsky, 2003),
the excellent agreement between clinical data and the model can
be considered a validation of the model extension.
When we simulated the effect of rivaroxaban exposure com-
bined with the residual warfarin effect after discontinuation of
warfarin, we demonstrated a strong synergistic effect. This find-
ing can be explained by the fact that inhibition by warfarin leads
to lower levels of Factor X, which resulted directly in lower levels
of free Factor Xa and Factor Xa–Factor Va (prothrombinase com-
plex). This inhibition is further enhanced by the fact that both its
substrate thrombin and the Factor X activation systems (intrin-
sic and extrinsic tenase) are present at lower levels. Consequently,
there is a higher level of inhibition when both free Factor Xa
and Factor Xa–Factor Va are targeted by rivaroxaban (Perzborn
et al., 2005). As expected, the synergistic effect of residual war-
farin action on the rivaroxaban effect decreased over time and
became negligible for a typical in silico patient after 2–3 days if
the treatment with warfarin was discontinued at an INR of 2.5,
in-line with guidelines for the treatment of patients with atrial fib-
rillation treated for the prevention of stroke (Ageno et al., 2012).
For simulations with a long warfarin half-life the synergistic effect
lasted longer.
To relate our simulations to clinically relevant scenarios for the
switching of a patient from warfarin to rivaroxaban, we applied a
set of efficacy and safety criteria. These criteria were established
previously to derive the therapeutic window for rivaroxaban. The
criteria were based on a comparison with warfarin effects under
several simulated coagulation scenarios (Table 3) and allowed the
identification of rivaroxaban exposure and related doses applied
during the decay phase of the warfarin effect complying with
the intended therapeutic effect. The outcome of the analysis was
translated into nomograms for typical Caucasian and Japanese
patients (Figures 6, 7), higher and lower initial INR starting val-
ues (Figure 8), and patients with high and low warfarin half-life
(Figure 9). These scenarios were chosen to show robustness of
the results within the range of warfarin-related variability and
slightly exceeding its therapeutic range. Examples for rivaroxaban
dosing schedules that fulfill the therapeutic criteria are indicated
within the nomograms. Of note, although not depicted explic-
itly, these graphs also allow evaluation of the potential impact
of pharmacokinetic variability of rivaroxaban. Depending on the
simulated conditions, our analysis suggested different bridging
schedules. Extreme situations such as starting at a sub-therapeutic
INR value of 1.5 allowed a flat dosing of the target rivaroxa-
ban dose for Caucasian patients (rivaroxaban 20mg once daily)
immediately after discontinuation (Figure 8A). Simulations for
typical Caucasian patients starting at an INR of 2.5 suggested
starting rivaroxaban treatment with a bridging dose of 10mg on
day 1 after discontinuation of warfarin followed by standard treat-
ment with 20mg once daily from day 2 onwards. For patients
starting at a higher INR value of 3.5 (Figure 8B) as well as patients
starting at INR 2.5 but with a long warfarin half-life (Figure 9B),
the suggested rivaroxaban schedule was shifted by 1 day.
Compared with Caucasian patients, Japanese patients have a
higher exposure to rivaroxaban owing to their lower clearance
via cytochrome P450 2C9 (Hori et al., 2012). Population differ-
ences in warfarin-relevant enzymes, such as vitamin K epoxide
reductase complex subunit 1 (VKORC1) and gamma-glutamyl
carboxylase (GGCX) (Kimura et al., 2007), were not explic-
itly included in the model but are implicitly represented by the
adjustment of the initial steady-state condition in the Japanese
version of the coagulation model. For typical Japanese patients
(Figure 7), the suggested bridging dose on days 1 and 2 was
rivaroxaban 10mg once daily followed by 15mg once daily from
day 3 onwards. The lower final doses of rivaroxaban match the
Japanese label (Bayer Yakuhin Ltd., 2012; Hori et al., 2012). The
rationale to test the reduced dose of rivaroxaban specifically in
Japanese patients was based on the higher exposure data in this
population and the lower warfarin target INR in Japanese clini-
cal practice (Hori et al., 2012). It should also be noted that the
reduced dose of 15mg once-daily rivaroxaban is only approved
in Japan but this dosing regimen may not be applicable in other
Asian countries. All bridging scenarios described above (reduced
bridging dose followed by standard treatment) comply with the
stricter criteria for patients at high risk of bleeding. For all patients
without a high risk of bleeding, flat dosing schedules starting with
the target rivaroxaban dose instead of the reduced bridging dose
comply with the safety and efficacy criteria.
We also simulated the effect of factor deficiencies in non-
vitamin K-dependent factors (Factors I, V, VIII, and XI), because
these would not necessarily be compensated for by titration of
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warfarin to a target INR. The predicted safety and efficacy corri-
dors changed only for severe over- or under-expression of these
factors (Supplementary Material 2). We conclude that this find-
ing is only relevant for patients who previously showed clinical
symptoms. This monovariate sensitivity analysis also indicated
that our findings are robust against plausible variability of fac-
tor concentrations in non-hemophilic and non-thrombophilic
patient populations.
We restricted our assessment to the typical simulation behav-
ior of individual patients, representing the mean plasma PK after
rivaroxaban dosing as well as typical short, intermediate, and
long half-lives of warfarin. As a consequence, our simulations
do not represent variability in a population of patients switching
from warfarin to rivaroxaban. In clinical practice, clinicians will
encounter higher as well as lower INR values in their patients. We
complemented our analysis of typical behavior with an investi-
gation of the potential impact of different (baseline) expression
levels of coagulation factors not dependent on vitamin K. During
model development, model parameters were selected such that
they are aligned with respective (microscopic) parameters pro-
vided by the literature and that simulated systemic properties
(e.g., coagulation times, amount of thrombin generated, response
to different types of pharmacologic interventions) are aligned
with these systemic properties reported in the literature.
Our model-based assessment provides mechanistic insight
into the interaction of warfarin and rivaroxaban during the
switching period between the two treatments. It supports prod-
uct information for rivaroxaban in the United States and Europe
(US Prescribing Information; European Summary of Product
Characteristics for rivaroxaban) (Bayer Pharma, 2014; Janssen
Pharmaceuticals Inc., 2014). When switching patients with atrial
fibrillation from warfarin to rivaroxaban, the US Prescribing
Information recommends to discontinue warfarin and if the
INR is below 3.0 to start rivaroxaban on the following day
(Janssen Pharmaceuticals Inc., 2014). The European Summary
of Product Characteristics broadly concurs with this advice (the
recommended INR is ≤3.0). For patients treated for deep vein
thrombosis and/or pulmonary embolism and for prevention
of recurrent deep vein thrombosis and pulmonary embolism,
the recommendation is to discontinue VKA therapy and initi-
ate rivaroxaban when the INR is ≤2.5 (Bayer Pharma, 2014).
These INR-based switching strategies provide a clinically feasible
approach to maximize safety and efficacy during the switching
period by characterization of patients prior to switching by mean
of the well-established INR value. Our simulations for initial
INR values of 2.5 versus 3.5 illustrate the relevance of the INR
threshold (Figures 6, 8B). In the latter case, simulations suggested
initiation of rivaroxaban therapy later than day 1 after discontin-
uation, which would be the practical outcome of an INR value of
3.5 in the clinic. As discussed above, efficacious and safe thera-
pies with different anticoagulants usually require different levels
of biomarkers, or even different biomarkers to characterize the
drug effect (for example, aPTT is a more relevant test than PT
for direct thrombin inhibitors). INR is appropriate only for mea-
suring the anticoagulant activity of VKAs. It is not appropriate
for assessing anticoagulation with rivaroxaban (Bayer Pharma,
2014; Janssen Pharmaceuticals Inc., 2014) or coagulation status
during the transition fromwarfarin to rivaroxaban (Kubitza et al.,
2005a,b). The use of INR only prior to dosing of rivaroxaban
consistently implements this fact.
LEARNING POINTS
The efficacy and safety nomograms defined by our simulations
support the switching strategies provided in the Summary of
Product Characteristics and Prescribing Information for rivarox-
aban (Bayer Pharma, 2014; Janssen Pharmaceuticals Inc., 2014).
There is no biomarker that predicts clinical consequences of the
combined effect of rivaroxaban and warfarin in the transition
phase. Large-scale clinical trials focusing on clinical outcomes of
different bridging options at low or high INR in the therapeutic
range of warfarin are not feasible. Simulations of different clini-
cally realistic scenarios are presented and provide clinicians with
a mechanistic pharmacologic rationale for these strategies and
underline the relevance of the recommendations.
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SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://www.frontiersin.org/journal/10.3389/fphys.
2014.00417/abstract
Supplementary Material 1 | Information pack including specification of
model parameters and codes used for the reproduction of study
simulations. Simulations were generated using the following versions of
the BTS software platform: MoBi® 2.3, MoBi® Toolbox for Matlab® 2.3.
This pack provides information on how to download the software, how to
re-run the simulations and how to reproduce the graphical
representations.
Supplementary Material 2 | Nomograms for in silico patients with
different factor abnormalities, including over-expression and
under-expression of the non-vitamin K-dependent factors I, V, VIII, and XI.
Factor deficiencies are indicated by x-fold change compared with normal
values and range from 0.01 to 5. The x-axis describes the time after
discontinuation of warfarin and the y-axis corresponds to rivaroxaban
exposure. Blue and red lines correspond to the edges of the safety and
efficacy region. The strong extrinsic trigger (TF = 10−11 M) was assumed
to be the relevant safety scenario. The weak extrinsic trigger
(TF = 10−14 M) was considered to be the relevant efficacy scenario.
Rivaroxaban exposure above the dashed red line is considered to be safe
and exposure below the dashed blue line is considered to be efficacious
for most patients. The region between the solid red and solid blue lines
describes the exposure range to which patients with a high risk of
bleeding or thrombosis should be dosed. Patients with a high risk of
bleeding should stay below the exposure limit represented by the solid
red line. Patients with a high risk of thrombosis should stay above the
exposure limit represented by the solid blue line. Alternative y-axes
convert rivaroxaban exposure into mean plasma concentration (Cmean),
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maximum plasma concentration (Cmax), and minimum plasma
concentration (Ctrough) values for the different dosing regimens studied (5,
10, 15, and 20mg once daily [OD]). These nomograms do not account for
pharmacokinetic variability or uncertainty in parameters. However, the
potential impact of pharmacokinetic variability of rivaroxaban can also be
evaluated from these graphs although this is not depicted explicitly. To
extract text information from the figure panels, such as labels of x-and
y-axes or other parameters, please zoom into the panel of interest. INR,
international normalized ratio.
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